NYSE:PFEPharmaceuticals
Pfizer (PFE) Valuation Check After New Oncology Data And Priority Review For Cancer Regimen
Pfizer (PFE) is back in focus after unveiling extensive new oncology data at the American Society of Clinical Oncology meeting and securing FDA Priority Review for a PADCEV plus Keytruda bladder cancer regimen.
See our latest analysis for Pfizer.
Despite the fresh oncology data and the FDA Priority Review, Pfizer’s share price at US$26.79 has had mixed momentum, with a 6.39% year to date share price return and a 24.66% total shareholder return over the past year, in contrast with weaker three...